Rad6B acts downstream of Wnt signaling to stabilize β-catenin: Implications for a novel Wnt/β-catenin target

Journal of Molecular Signaling

Volumn 6, Issue , 2011, Pages

  Gerard, Brigitte ^a,b   Tait, Larry ^a,b   Nangia Makker, Pratima ^a,b   Shekhar, Malathy P V ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUS MUSCULUS;

EID: 79960554597     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-6-6     Document Type: Article

References (52)

1. Dierick H, Bejsovec A. Cellular mechanisms of wingless/Wnt signal transduction. Curr Top Dev Biol 1999, 43:153-190.
2. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Ann Rev Cell Dev Biol 2004, 20:781-810.
3. Seidensticker MJ, Behrens J. Biochemical interactions in the wnt pathway. Biochim Biophys Acta 2000, 1495:168-182. 10.1016/S0167-4889(99)00158-5, 10656974.
4. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006, 127:469-480. 10.1016/j.cell.2006.10.018, 17081971.
5. Polakis P. Wnt signaling and cancer. Genes & Dev 2000, 14:1837-1851.
6. Kitagawa M, Hatakeyama S, Shirane M. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J 1999, 18:2401-2410. 10.1093/emboj/18.9.2401, 1171323, 10228155.
7. Candidus S, Bischoff P, Becker KF, Hofler H. No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res 1996, 56:49-52.
8. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands R, Egeblad M, Cowin P, Werb Z, Tan LK, Rosen JM, Varmus HE. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 2003, 100:15853-15858. 10.1073/pnas.2136825100, 307657, 14668450.
9. Brennan KR, Brown AMC. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004, 9:119-131.
10. Turashvili G, Bouchal J, Burkadze G, Kolar Z. Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 2006, 73:213-223. 10.1159/000098207, 17314492.
11. Lindvall C, Bu W, Williams BO, Li Y. Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Review 2007, 3:157-168.
12. Schlosshauer PW, Brown SA, Eisinger K, Yan Q, Guglielminetti ER, Parsons R, Ellenson LH, Kitajewski J. APC truncation and increased beta-catenin levels in a human breast cancer cell line. Carcinogenesis 2000, 21:1453-1456. 10.1093/carcin/21.7.1453, 10874025.
13. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther 2004, 3:36-41. 10.4161/cbt.3.1.561, 14739782.
14. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000, 97:4262-4266. 10.1073/pnas.060025397, 18221, 10759547.
15. Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, Markaki S, Keramopoulos A. Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol 2006, 19:556-563. 10.1038/modpathol.3800562, 16474376.
16. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988, 55:619-625. 10.1016/0092-8674(88)90220-6, 3180222.
17. Lane TF, Leder P. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 1997, 15:2133-2144. 10.1038/sj.onc.1201593, 9393971.
18. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adélaïde J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pébusque MJ. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001, 20:5810-5817. 10.1038/sj.onc.1204706, 11593386.
19. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stöhr R, Simon R, Sauter G, Leibiger H, Essers L, Weber B, Hermann K, Rosenthal A, Hartmann A, Dahl E. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004, 25:641-649.
20. Liu C-C, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 2010, 107:5136-5141. 10.1073/pnas.0911220107, 2841938, 20194742.
21. Jentsch S, McGrath JP, Varshavsky A. The yeast DNA repair gene RAD6 encodes a ubiquitin-conjugating enzyme. Nature 1987, 329:131-134. 10.1038/329131a0, 3306404.
22. Shekhar MP, Gerard B, Pauley RJ, Williams BO, Tait L. Rad6B is a positive regulator of β-catenin stabilization. Cancer Res 2008, 68:1741-1750. 10.1158/0008-5472.CAN-07-2111, 18339854.
23. Shekhar MP, Lyakhovich A, Visscher DW, Heng H, Kondrat N. Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. Cancer Res 2002, 62:2115-2124.
24. Shekhar MP, Tait L, Gerard B. Essential role of T-Cell Factor/β-catenin in regulation of Rad6B: a potential mechanism for Rad6B overexpression in breast cancer cells. Mol Cancer Res 2006, 4:729-745. 10.1158/1541-7786.MCR-06-0136, 17050667.
25. Brennan K, Gonzales-Sancho JM, Castelo-Soccio LA, Howe LR, Brown AMC. Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize β-catenin independently of Frizzled proteins. Oncogene 2004, 23:4873-4884. 10.1038/sj.onc.1207642, 2494703, 15064719.
26. Metcalfe C, Mendoza-Topaz C, Mieszczanek J, Bienz M. Stability elements in the LRP6 cytoplasmic tail confer efficient signalling upon DIX-dependent polymerization. J Cell Sci 2010, 123:1588-1599. 10.1242/jcs.067546, 2858023, 20388731.
27. Shekhar MP, Tait L, Pauley RJ, Wu GS, Santner SJ, Nangia-Makker P, Shekhar V, Nassar H, Visscher DW, Heppner GH, Miller FR. Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biol Ther 2008, 7:1774-1782. 10.4161/cbt.7.11.6781, 18787417.
28. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004, 6:497-506. 10.1016/j.ccr.2004.09.032, 15542433.
29. McEwen DG, Peifer M. Wnt signaling: The Naked truth?. Curr Biol 2001, 11:R524-R526. 10.1016/S0960-9822(01)00310-4, 11470426.
30. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P, Glinka A, Niehrs C. Casein kinase 1γ couples Wnt receptor activation to cytoplasmic signal transduction. Nature 2005, 438:867-872. 10.1038/nature04170, 16341016.
31. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005, 438:873-877. 10.1038/nature04185, 2100418, 16341017.
32. Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, Almeida K, Wang J, Doble B, Woodgett J, Wynshaw-Boris A, Hsieh JC, He X. Initiation of Wnt signalling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 135:367-375.
33. Piao S, Lee SH, Kim H, Yum S, Stamos JL, Xu Y, Lee SJ, Lee J, Oh S, Han JK, Park BJ, Weis WI, Ha NC. Direct inhibition of GSK3β by the phosphorylated cytoplasmic domain of LRP6 in Wnt/β-catenin signalling. PLoS ONE 2008, 3:e4046. 10.1371/journal.pone.0004046, 2603313, 19107203.
34. Wu G, Huang H, Garcia Abreu J, He X. Inhibition of GSK3 phosphorylation of β-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS ONE 2009, 4:e4926. 10.1371/journal.pone.0004926, 2654145, 19293931.
35. Cselenyi CS, Jernigan KK, Tahinci E, Thorne CA, Lee LA, Lee E. LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3's phosphorylation of β-catenin. Proc Natl Acad Sci USA 2008, 105:8032-8037. 10.1073/pnas.0803025105, 2430354, 18509060.
36. Mi K, Dolan PJ, Johnson GV. The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity. J Biol Chem 2006, 281:4787-4794.
37. MacDonald BT, Tamai K, He X. Wnt/β-catenin signalling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26. 10.1016/j.devcel.2009.06.016, 2861485, 19619488.
38. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009, 1796:75-90.
39. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nature Reviews Mol Cell Biol 2002, 3:155-166.
40. Yook JI, Li XY, Ota I, Fearon ER, Weiss SJ. Wnt dependent regulation of the E-cadherin repressor snail. J Biol Chem 2005, 280:11740-11748. 10.1074/jbc.M413878200, 15647282.
41. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, Ben-Ze'ev A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol 2003, 163:847-857. 10.1083/jcb.200308162, 2173691, 14623871.
42. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann ER. Differentiation state and invasiveness of human breast cancer cell lines. Breast cancer Res & Treat 1994, 31:325-335. 10.1007/BF00666165, 21768129.
43. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 2001, 3:793-801. 10.1038/ncb0901-793, 11533658.
44. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004, 100:2084-2092. 10.1002/cncr.20232, 15139049.
45. Prasad CP, Gupta SD, Rath G, Ralhan R. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, disheveled and cyclin D1 expression. Oncology 2007, 73:112-117. 10.1159/000120999, 18337623.
46. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009, 69:5364-5373. 10.1158/0008-5472.CAN-08-4135, 2782448, 19549913.
47. Zhang J, Li Y, Liu Q, Lu W, Bu G. Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene 2010, 29:539-549. 10.1038/onc.2009.339, 2813429, 19881541.
48. Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP, Brisken C. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci USA 2006, 103:3799-3804. 10.1073/pnas.0600065103, 1450156, 16501043.
49. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003, 201:204-212. 10.1002/path.1449, 14517837.
50. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res & Treat 2007, 105:319-326. 10.1007/s10549-006-9463-x, 21768129.
51. Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, Hendrix MJ. Association between keratin and vimentin expression, malignant phenotype, and survival in post-menopausal breast cancer patients. Clin Cancer Res 1999, 5:2698-26703.
52. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006, 12:4185-4191. 10.1158/1078-0432.CCR-06-0353, 16857790.